Moleculin Biotech, Inc. announced that in preliminary animal studies, a second of its lead drugs, WP1732, has demonstrated enhanced activity in combination with checkpoint blockade antibodies in pancreatic cancer. After its sponsored research demonstrated that WP1066 was able to enhance immune checkpoint activity in a pancreatic cancer animal model. This is significant for several reasons. It shows that this is a consistent capability across its platform of STAT3 inhibitors and it further supports independent research suggesting that STAT3 may be a key to enabling checkpoint blockade activity in otherwise resistant tumors. Expansion of the WP1732 and WP1066 in vivo studies is in progress.